Screener
Vor Biopharma VOR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $17,595 | $26,701 |
| General and administrative | 17,565 | 6,590 |
| Total operating expenses | $35,160 | $33,291 |
| Loss from operations | (35,160) | (33,291) |
| Other income (expense): | ||
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
| Total other (expense) income | (184,425) | 805 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's operating income?
- Vor Biopharma (VOR) reported operating income of -$35.16M in Q1 2026.
- How has Vor Biopharma's operating income changed year-over-year?
- Vor Biopharma's operating income decreased by 5.6% year-over-year, from -$33.29M to -$35.16M.
- What is the long-term trend for Vor Biopharma's operating income?
- Over 4 years (2021 to 2025), Vor Biopharma's operating income has grown at a 52.3% compound annual growth rate (CAGR), from -$69.02M to -$371.64M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Vor Biopharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude